Agios Pharmaceuticals (AGIO) Operating Expenses (2012 - 2026)

Agios Pharmaceuticals has reported Operating Expenses for 15 years, with the latest figure at $130.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 13.36% year-over-year to $130.8 million; the trailing twelve-month figure through Mar 2026 stood at $541.6 million (up 13.46% YoY), and the FY2025 full-year result was $526.2 million, up 13.83% from the prior year.
• Operating Expenses for Q1 2026 stood at $130.8 million, down from $141.5 million in the prior quarter.
• The five-year high for Operating Expenses was $141.5 million in Q4 2025, with the low at $94.6 million in Q3 2022.
• Historically, Operating Expenses has averaged $114.2 million across 5 years, with a median of $111.8 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Expenses declined 5.64% — and 2025, when it advanced 21.92%.
• Agios Pharmaceuticals' Operating Expenses stood at $103.5 million in 2022, then rose by 9.56% to $113.4 million in 2023, then advanced by 19.75% to $135.8 million in 2024, then advanced by 4.26% to $141.5 million in 2025, then retreated by 7.61% to $130.8 million in 2026.
• The last three Operating Expenses figures came in at $130.8 million (Q1 2026), $141.5 million (Q4 2025), and $129.7 million (Q3 2025), per Business Quant data.